vTv Therapeutics (VTVT) Net Cash Flow (2014 - 2026)

vTv Therapeutics has disclosed Net Cash Flow across 13 years of filings, most recently posting $9.2 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at $9.2 million, up 260.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $67.0 million (up 416.22% YoY), and the FY2025 annual result was $52.2 million, up 91.16% from the prior year.
• Net Cash Flow came in at $9.2 million for Q1 2026 at vTv Therapeutics, up from -$9.6 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $72.6 million in Q3 2025 to a low of -$9.6 million in Q4 2025.
• The 5-year median for Net Cash Flow is -$3.2 million (2022), against an average of $5.0 million.
• Across the five-year window, Net Cash Flow plunged 499.42% in 2024 and jumped 1935.2% in 2025, its largest moves.
• vTv Therapeutics' Net Cash Flow stood at -$3.2 million in 2022, then soared by 137.6% to $1.2 million in 2023, then slumped by 499.42% to -$4.8 million in 2024, then tumbled by 98.38% to -$9.6 million in 2025, then surged by 195.63% to $9.2 million in 2026.
• The last three Net Cash Flow figures came in at $9.2 million (Q1 2026), -$9.6 million (Q4 2025), and $72.6 million (Q3 2025), per Business Quant data.